Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Glioma 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Cholangiocarcinoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

olutasidenib 1fludarabine 1Dexamethasone 1Decitabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Myeloid Malignancies × olutasidenib × Clear all
NCT06668584 2026-03-04

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

M.D. Anderson Cancer Center

Phase 2 Recruiting
31 enrolled

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡